Publications - IR Sant Pau

Search

01/05/2022 Extensive lichen planopilaris as exclusive lichenoid reaction secondary to pembrolizumab in a patient with metastatic melanoma

Garcia-Melendo, C, Morales-Munera, CE, Dalmau, J, Cubiro, X, Lopez-Sanchez, C, Mozos, A, Yelamos, O. Extensive lichen planopilaris as exclusive lichenoid reaction secondary to pembrolizumab in a patient with metastatic melanoma. Dermatologic Therapy. 2022; 35(5)DOI:10.1111/dth.15388. PMID:35174945. IF:3.600(Q1/3D).

03/04/2022 Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis

Reich, K, Conrad, C, Kristensen, LE, Smith, SD, Puig, L, Rich, P, Sapin, C, Holzkaemper, T, Koppelhus, U, Schuster, C. Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(3)DOI:10.1080/09546634.2021.1892024. PMID:33641593. IF:2.900(Q2/4D).

01/04/2022 Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome

Iznardo, H, Bredrup, C, Bernal, S, Gladkauskas, T, Mascaro, JM, Roe, E, Baselga, E. Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome. AMERICAN JOURNAL OF MEDICAL GENETICS PART A. 2022; 188(4)DOI:10.1002/ajmg.a.62603. PMID:34894066. IF:2.000(Q3/8D).

01/02/2022 Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

del Alcazar, E, Lopez-Ferrer, A, Martinez-Domenech, A, Ruiz-Villaverde, R, Llamas-Velasco, MD, Rocamora, V, Julia, M, Notario, J, Fernandez-Freire, LR, Sahuquillo-Torralba, A, Vidal, D, Rivera, R, Carretero, G, Mateu, A, de la Cueva, P, Carrascosa, JM. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. Dermatologic Therapy. 2022; 35(2)DOI:10.1111/dth.15231. PMID:34820971. IF:3.600(Q1/3D).

01/02/2022 Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial

Thaci, D, Strober, B, Gordon, KB, Foley, P, Gooderham, M, Morita, A, Papp, KA, Puig, L, Menter, MA, Colombo, MJ, Elbez, Y, Kisa, RM, Ye, JN, Napoli, AA, Wei, L, Banerjee, S, Merola, JF, Gottlieb, AB. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. Dermatology and Therapy. 2022; 12(2)DOI:10.1007/s13555-021-00649-y. PMID:35025062. IF:3.400(Q2/3D).

01/01/2022 Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis

Armstrong, AW, Soliman, AM, Betts, KA, Wang, Y, Gao, YW, Stakias, V, Puig, L. Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis. Dermatology and Therapy. 2022; 12(1)DOI:10.1007/s13555-021-00647-0. PMID:34862951. IF:3.400(Q2/3D).

01/01/2022 Treatment Options and Goals for Patients with Generalized Pustular Psoriasis

Krueger, J, Puig, L, Thaci, D. Treatment Options and Goals for Patients with Generalized Pustular Psoriasis. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(SUPPL 1)DOI:10.1007/s40257-021-00658-9. PMID:35061230. IF:7.300(Q1/1D).

01/01/2022 Pathophysiology of Generalized Pustular Psoriasis

Marrakchi, S, Puig, L. Pathophysiology of Generalized Pustular Psoriasis. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(SUPPL 1)DOI:10.1007/s40257-021-00655-y. PMID:35061228. IF:7.300(Q1/1D).

01/01/2022 Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey (Oct, 10.1007/s13555-021-00635-4, 2021)

Lebwohl, M, Langley, RG, Paul, C, Puig, L, Reich, K, van de Kerkhof, P, Wu, HL, Richter, S, Jardon, S, Gisondi, P. Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey (Oct, 10.1007/s13555-021-00635-4, 2021). Dermatology and Therapy. 2022; 12(1)DOI:10.1007/s13555-021-00656-z. PMID:34989998. IF:3.400(Q2/3D).

01/01/2022 Nodular scabies mimicking breast cancer skin metastasis

Cubiro, X, Garcia-Melendo, C, Tubau-Prims, C, Puig, L. Nodular scabies mimicking breast cancer skin metastasis. Indian Journal of Dermatology Venereology & Leprology. 2022; 88(1)DOI:10.25259/IJDVL_63_2021. PMID:34623049. IF:2.900(Q2/4D).

01/12/2021 Integra as Firstline Treatment for Scalp Reconstruction in Elderly Patients

Mogedas-Vegara, A, Agut-Busquet, E, Marsal, MY, Aguilar, JL, de la Torre, OE. Integra as Firstline Treatment for Scalp Reconstruction in Elderly Patients. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY. 2021; 79(12)DOI:10.1016/j.joms.2021.07.009. PMID:34391723. IF:2.136(Q4/8D).

01/11/2021 Ultrasonographic patterns of cutaneous sarcoidosis

Lopez-Llunell, C, Romani, J, Roe, E, Giavedoni, P, Vidal, D, Wortsman, X. Ultrasonographic patterns of cutaneous sarcoidosis. JOURNAL OF ULTRASOUND IN MEDICINE. 2021; 40(11)DOI:10.1002/jum.15631. PMID:33459396. IF:2.754(Q2/4D).

01/11/2021 New perspectives on the treatment of hidradenitis suppurativa

Amat-Samaranch, V, Agut-Busquet, E, Vilarrasa, E, Puig, L. New perspectives on the treatment of hidradenitis suppurativa. Therapeutic Advances in Chronic Disease. 2021; 12DOI:10.1177/20406223211055920. PMID:34840709. IF:4.970(Q2/3D).

01/11/2021 Should methyldibromo glutaronitrile continue to be used in the European baseline Series? A REIDAC national cross-sectional study

Mercader-Garcia, P, Pastor-Nieto, MA, Gonzalez-Perez, R, Cordoba-Guijarro, S, Gimenez-Arnau, AM, Ruiz-Gonzalez, I, Mora-Fernandez, V, Miquel, J, Silvestre-Salvador, JF, Ortiz-Frutos, FJ, Sanz-Sanchez, T, Rodriguez-Serna, M, Perez-Feal, P, Sanchez-Perez, J, Heras-Mendaza, F, Serra-Baldrich, E, Zaragoza-Ninet, V, Hervella-Garces, M, Gatica-Ortega, ME, Garcia-Doval, I, Descalzo, MA, Borrego, L. Should methyldibromo glutaronitrile continue to be used in the European baseline Series? A REIDAC national cross-sectional study. CONTACT DERMATITIS. 2021; 85(5)DOI:10.1111/cod.13837. PMID:33745152. IF:6.419(Q1/1D).

01/11/2021 Sequelae following infantile haemangiomas treated with propranolol

Baselga, E, El Hachem, M, Diociaiuti, A, Carnevale, C, Downey, C, Roe, E, Mascaro, P, Neri, I, Leuzzi, M, Bernabeu-Wittel, J, Monserrat-Garcia, MT, Ortiz-Prieto, A, Torrelo, A, Knopfel, N, Vercellino, N, Manunza, F, Oranges, T, Bassi, A, Gonzalez-Ensenat, MA, Vicente, A, Gich, I, Puig, L. Sequelae following infantile haemangiomas treated with propranolol. EUROPEAN JOURNAL OF DERMATOLOGY. 2021; 31(6)DOI:10.1684/ejd.2021.4172. PMID:35107070. IF:2.805(Q2/5D).

01/08/2021 Quality of Life in Hidradenitis Suppurativa: Validation of the HSQoL-24

Marron, SE, Gomez-Barrera, M, Aragones, LT, Goni-Navarro, A, Vilarrasa-Rull, E, Diaz-Diaz, RM, Garcia-Latasa De Aranibar, FJ, Campos-Rodenas, R, Fuentelsaz-Del Barrio, V, Gilaberte-Calzada, Y, Gracia-Cazana, T, Morales-Callaghan, AM, Ros-Abarca, S, Madrid-Alvarez, MB, Puig, L. Quality of Life in Hidradenitis Suppurativa: Validation of the HSQoL-24. ACTA DERMATO-VENEREOLOGICA. 2021; 101DOI:10.2340/00015555-3905. PMID:34427316. IF:3.875(Q2/3D).

01/07/2021 Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study

Torres, T, Puig, L, Vender, R, Lynde, C, Piaserico, S, Carrascosa, JM, Gisondi, P, Dauden, E, Conrad, C, Mendes-Bastos, P, Ferreira, P, Leite, L, Lu, JSD, Valerio, J, Bruni, M, Messina, F, Nidegger, A, Llamas-Velasco, M, del Alcazar, E, Mufti, A, White, K, Caldarola, G, Teixeira, L, Romanelli, P, Desai, K, Gkalpakiotis, S, Romanelli, M, Yeung, JN, Nogueira, M, Chiricozzi, A. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2021; 22(4)DOI:10.1007/s40257-021-00598-4. PMID:33786754. IF:6.233(Q1/2D).

01/07/2021 Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey

Mahil, SK, Yates, M, Langan, SM, Yiu, ZZN, Tsakok, T, Dand, N, Mason, KJ, McAteer, H, Meynell, F, Coker, B, Vincent, A, Urmston, D, Vesty, A, Kelly, J, Lancelot, C, Moorhead, L, Bachelez, H, Bruce, IN, Capon, F, Contreras, CR, Cope, AP, de la Cruz, C, Di Meglio, P, Gisondi, P, Hyrich, K, Jullien, D, Lambert, J, Marzo-Ortega, H, McInnes, I, Naldi, L, Norton, S, Puig, L, Sengupta, R, Spuls, P, Torres, T, Warren, RB, Waweru, H, Weinman, J, Griffiths, CEM, Barker, JN, Brown, MA, Galloway, JB, Smith, CH, PsoProtect CORE-UK Study Grp. Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. BRITISH JOURNAL OF DERMATOLOGY. 2021; 185(1)DOI:10.1111/bjd.19755. PMID:33368145. IF:11.113(Q1/1D).

01/01/2023 High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting

Martos-Cabrera, L, Llamas-Velasco, M, Armesto, S, Herrera-Acosta, E, Vidal, D, Vilarrasa, E, Rivera-Diaz, R, de la Cueva, P, Martorell-Calatayud, A, Ballesca, F, Belinchon, I, Carretero, G, Rodriguez, L, Romero-Mate, A, Pujol-Montcusi, J, Salgado-Boquete, L, Sahuquillo-Torralba, A, Coto-Segura, P, Baniandres, O, Feltes, R, Alsina, M, Dauden, E. High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting. INTERNATIONAL JOURNAL OF DERMATOLOGY. 2023; 62(3)DOI:10.1111/ijd.16365. PMID:35867958. IF:3.500(Q1/3D).

01/01/2023 Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry

Muniesa C., Gallardo F., García-Doval I., Estrach M.T., Combalia A., Morillo-Andújar M., De la Cruz-Vicente F., Machan S., Moya-Martínez C., Rovira R., Sanchez-Gonzalez B., Acebo E., Amutio E., Penate, Y, Losada-Castillo, MD, García-Muret M.P., Iznardo H., Román-Curto C., Canueto, J, Fernández-de-Misa R., Flórez Á., Izu R.M., Torres-Navarro I., Zayas A., Pérez-Paredes G., Blanes M., Yanguas J.I., Pérez-Ferriols A., Callejas-Charavia M., Ortiz-Romero P.L., Pérez-Gil A., Prieto-Torres L., González-Barca E., Servitje O.. Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(1)DOI:10.1111/jdv.18563. PMID:36017748. IF:8.500(Q1/1D).

01/12/2022 Clinical and ultrasonography follow-up of five cases of calcinosis cutis successfully treated with intralesional sodium thiosulfate

Tubau, C, Cubiro, X, Amat-Samaranch, V, Garcia-Melendo, C, Puig, L, Roe-Crespo, E. Clinical and ultrasonography follow-up of five cases of calcinosis cutis successfully treated with intralesional sodium thiosulfate. Journal Of Ultrasound. 2022; 25(4)DOI:10.1007/s40477-022-00665-4. PMID:35397096. IF:(Q/D).

01/12/2022 Psoriasis treatment: no more room on the summit?

Puig, L. Psoriasis treatment: no more room on the summit?. BRITISH JOURNAL OF DERMATOLOGY. 2022; 187(6)DOI:10.1111/bjd.21848. PMID:36065496. IF:10.300(Q1/1D).

01/12/2022 A Response to: Letter to the Editor Regarding Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis

Armstrong, AW, Soliman, AM, Betts, KA, Wang, Y, Gao, YW, Stakias, V, Puig, L. A Response to: Letter to the Editor Regarding Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. Dermatology and Therapy. 2022; 12(12)DOI:10.1007/s13555-022-00812-z. PMID:36271222. IF:3.400(Q2/3D).

01/11/2022 Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO)

Pinter, A, Puig, L, Schakel, K, Reich, A, Zaheri, S, Costanzo, A, Tsai, TF, Smith, SD, Lynde, C, Brnabic, A, Reed, C, Hill, J, Schuster, C, Riedl, E, Paul, C. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(11)DOI:10.1111/jdv.18376. PMID:35766124. IF:9.200(Q1/1D).

01/11/2022 SEB-induced IL-13 production in CLA(+) memory T cells defines Th2 high and Th2 low responders in atopic dermatitis

Sans-De San Nicolas, L, Figueras-Nart, I, Bonfill-Orti, M, De Jesus-Gil, C, Garcia-Jimenez, I, Guilabert, A, Curto-Barredo, L, Bertolin-Colilla, M, Ferran, M, Serra-Baldrich, E, Zalewska-Janowska, A, Wang, YH, Howell, MD, Pujol, RM, Santamaria-Babi, LF. SEB-induced IL-13 production in CLA(+) memory T cells defines Th2 high and Th2 low responders in atopic dermatitis. ALLERGY. 2022; 77(11)DOI:10.1111/all.15424. PMID:35773619. IF:12.400(Q1/1D).

01/11/2022 Deucravacitinib for the Treatment of Psoriatic Disease

Le, AM, Puig, L, Torres, T. Deucravacitinib for the Treatment of Psoriatic Disease. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(6)DOI:10.1007/s40257-022-00720-0. PMID:35960487. IF:7.300(Q1/1D).

01/11/2022 Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study

Torres, T, Puig, L, Vender, R, Yeung, J, Carrascosa, JM, Piaserico, S, Gisondi, P, Lynde, C, Ferreira, P, Bastos, PM, Dauden, E, Leite, L, Valerio, J, del Alcazar-Viladomiu, E, Rull, EV, Llamas-Velasco, M, Pirro, F, Messina, F, Bruni, M, Licata, G, Ricceri, F, Nidegger, A, Hugo, J, Mufti, A, Daponte, AI, Teixeira, L, Balato, A, Romanelli, M, Prignano, F, Gkalpakiotis, S, Conrad, C, Lazaridou, E, Rompoti, N, Papoutsaki, M, Nogueira, M, Chiricozzi, A. Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(6)DOI:10.1007/s40257-022-00722-y. PMID:35976568. IF:7.300(Q1/1D).

01/11/2022 European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations

Wollenberg, A, Kinberger, M, Arents, B, Aszodi, N, Valle, GA, Barbarot, S, Bieber, T, Brough, HA, Pinton, PC, Christen-Zach, S, Deleuran, M, Dittmann, M, Dressler, C, Fink-Wagner, AH, Fosse, N, Gaspar, K, Gerbens, L, Gieler, U, Girolomoni, G, Gregoriou, S, Mortz, CG, Nast, A, Nygaard, U, Redding, M, Rehbinder, EM, Ring, J, Rossi, M, Serra-Baldrich, E, Simon, D, Szalai, ZZ, Szepietowski, JC, Torrelo, A, Werfel, T, Flohr, C. European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(11)DOI:10.1111/jdv.18429. PMID:36056736. IF:9.200(Q1/1D).

01/10/2022 Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies

Thaci, D, Gerdes, S, Du Jardin, KG, Perrot, JL, Puig, L. Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies. Dermatology and Therapy. 2022; 12(10)DOI:10.1007/s13555-022-00793-z. PMID:36098877. IF:3.400(Q2/3D).

01/09/2022 European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy

Wollenberg, A, Kinberger, M, Arents, B, Aszodi, N, Valle, GA, Barbarot, S, Bieber, T, Brough, HA, Pinton, PC, Christen-Zach, S, Deleuran, M, Dittmann, M, Dressler, C, Fink-Wagner, AH, Fosse, N, Gaspar, K, Gerbens, L, Gieler, U, Girolomoni, G, Gregoriou, S, Mortz, CG, Nast, A, Nygaard, U, Redding, M, Rehbinder, EM, Ring, J, Rossi, M, Serra-Baldrich, E, Simon, D, Szalai, ZZ, Szepietowski, JC, Torrelo, A, Werfel, T, Flohr, C. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(9)DOI:10.1111/jdv.18345. PMID:35980214. IF:9.200(Q1/1D).

01/09/2022 HTLV-1/2 Infection in Blood Donors from a Non-Endemic Area (Catalonia, Spain) between 2008 and 2017: A 10-Year Experience

Piron, M, Salvador, F, Caballero, E, Sanchez-Montalva, A, Bes, M, Casamitjana, N, Puig, L, Molina, I, Sauleda, S. HTLV-1/2 Infection in Blood Donors from a Non-Endemic Area (Catalonia, Spain) between 2008 and 2017: A 10-Year Experience. Viruses-Basel. 2022; 14(9)DOI:10.3390/v14091975. PMID:36146780. IF:4.700(Q2/5D).

18/08/2022 Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis

Zozaya, N, Abdalla, F, Zamora, SA, Filgueiras, JB, Carrillo, JMC, Sanchez, OD, Sinisterra, FD, Garcia-Ruiz, A, Pinto, PH, Manfredi, A, Olmos, JM, Luna, PMD, Puig, L, Ros, S, HIdalgo-Vega, A. Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis. Expert Review of Pharmacoeconomics & Outcomes Research. 2022; 22(6)DOI:10.1080/14737167.2022.2063842. PMID:35404728. IF:2.300(Q3/7D).

18/08/2022 Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group

del Alcazar, E, Lopez-Ferrer, A, Martinez-Domenech, A, Julia, M, Ruiz-Villaverde, R, Fernandez-Freire, LR, Notario, J, Llamas-Velasco, M, Ferran, M, Carrascosa, JM. Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(6)DOI:10.1080/09546634.2022.2079596. PMID:35593480. IF:2.900(Q2/4D).

01/08/2022 Shear wave elastography as a potential tool for quantitative assessment of sinus tracts fibrosis in hidradenitis suppurativa

Iznardo, H, Vilarrasa, E, Roe, E, Puig, L. Shear wave elastography as a potential tool for quantitative assessment of sinus tracts fibrosis in hidradenitis suppurativa. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(8)DOI:10.1111/jdv.18116. PMID:35353931. IF:9.200(Q1/1D).

01/08/2022 Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and-3

Reich, K, Iversen, L, Puig, L, Lambert, J, Mrowietz, U, Saday, KK, Warren, RB. Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and-3. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(8)DOI:10.1111/jdv.18068. PMID:35279890. IF:9.200(Q1/1D).

01/08/2022 Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting

Chicharro, P, Llamas-Velasco, M, Armesto, S, Herrera-Acosta, E, Vidal, D, Vilarrasa, E, Rivera, R, De la Cueva, P, Martorell-Calatayud, A, Ballesca, F, Belinchon, I, Carretero, G, Rodriguez, L, Romero-Mate, A, Pujol-Montcusi, J, Salgado, L, Sahuquillo-Torralba, A, Coto-Segura, P, Baniandres-Rodriguez, O, Feltes, R, Alsina, M, Dauden, E. Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting. Dermatologic Therapy. 2022; 35(8)DOI:10.1111/dth.15653. PMID:35731640. IF:3.600(Q1/3D).

01/08/2022 IL-1 Family Cytokines in Inflammatory Dermatoses: Pathogenetic Role and Potential Therapeutic Implications

Iznardo, H, Puig, L. IL-1 Family Cytokines in Inflammatory Dermatoses: Pathogenetic Role and Potential Therapeutic Implications. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(16)DOI:10.3390/ijms23169479. PMID:36012744. IF:5.600(Q1/3D).

04/07/2022 Comorbidity identification and referral in atopic dermatitis: a consensus document

de Frutos, JO, Carretero, G, de Lucas, R, Puig, S, Serra, E, Castro, SG, Laserna, FR, Loza, E, Silvestre-Salvador, JF. Comorbidity identification and referral in atopic dermatitis: a consensus document. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(5)DOI:10.1080/09546634.2022.2067815. PMID:35435103. IF:2.900(Q2/4D).

01/07/2022 Vulvar allergic contact dermatitis caused by Magnolia officinalis bark extract

Amat-Samaranch, V, Lopez-Sanchez, C, Tubau, C, Puig, L, Serra-Baldrich, E. Vulvar allergic contact dermatitis caused by Magnolia officinalis bark extract. CONTACT DERMATITIS. 2022; 87(1)DOI:10.1111/cod.14101. PMID:35277988. IF:5.500(Q1/1D).

01/07/2022 Inter- and intra-observer variability in the selection of therapy for infantile hemangiomas among pediatric dermatologists in Spain

Colmenero, M, del Boz, J, Wittel, JB, Roe, E, Feito-Rodriguez, M, Vicente-Villa, MA, Martin-Santiago, A, Perez, SIP, Azon, A, Valdivielso-Ramos, M, Torrelo, A, Moya, AIS, Campos-Dominguez, M, Garnacho-Saucedo, G, Defez, JMA, Casano, AV, Tercedor-Sanchez, J, Alcala, R, Gonzalez-Enseyat, MA, Giacaman, A, Hernandez-Martin, A, Garcia, MTM, Bauza, A, Dominguez-Cruz, J, Garcia-Doval, I, Grau-Perez, M. Inter- and intra-observer variability in the selection of therapy for infantile hemangiomas among pediatric dermatologists in Spain. PEDIATRIC DERMATOLOGY. 2022; 39(4)DOI:10.1111/pde.15015. PMID:35504688. IF:1.500(Q4/8D).